Combination Therapy Accelerates Diabetic Wound Closure
Open Access
- 20 March 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3) , e92667
Abstract
Non-healing foot ulcers are the most common cause of non-traumatic amputation and hospitalization amongst diabetics in the developed world. Impaired wound neovascularization perpetuates a cycle of dysfunctional tissue repair and regeneration. Evidence implicates defective mobilization of marrow-derived progenitor cells (PCs) as a fundamental cause of impaired diabetic neovascularization. Currently, there are no FDA-approved therapies to address this defect. Here we report an endogenous PC strategy to improve diabetic wound neovascularization and closure through a combination therapy of AMD3100, which mobilizes marrow-derived PCs by competitively binding to the cell surface CXCR4 receptor, and PDGF-BB, which is a protein known to enhance cell growth, progenitor cell migration and angiogenesis. Wounded mice were assigned to 1 of 5 experimental arms (n = 8/arm): saline treated wild-type, saline treated diabetic, AMD3100 treated diabetic, PDGF-BB treated diabetic, and AMD3100/PDGF-BB treated diabetic. Circulating PC number and wound vascularity were analyzed for each group (n = 8/group). Cellular function was assessed in the presence of AMD3100. Using a validated preclinical model of type II diabetic wound healing, we show that AMD3100 therapy (10 mg/kg; i.p. daily) alone can rescue diabetes-specific defects in PC mobilization, but cannot restore normal wound neovascularization. Through further investigation, we demonstrate an acquired trafficking-defect within AMD3100-treated diabetic PCs that can be rescued by PDGF-BB (2 μg; topical) supplementation within the wound environment. Finally, we determine that combination therapy restores diabetic wound neovascularization and accelerates time to wound closure by 40%. Combination AMD3100 and PDGF-BB therapy synergistically improves BM PC mobilization and trafficking, resulting in significantly improved diabetic wound closure and neovascularization. The success of this endogenous, cell-based strategy to improve diabetic wound healing using FDA-approved therapies is inherently translatable.Keywords
This publication has 46 references indexed in Scilit:
- Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axisStem Cell Research, 2011
- A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in miceJournal of Clinical Investigation, 2011
- Sonic Hedgehog-Induced Functional Recovery After Myocardial Infarction Is Enhanced by AMD3100-Mediated Progenitor-Cell MobilizationJACC, 2011
- 17β-Estradiol Mobilizes Bone Marrow–Derived Endothelial Progenitor Cells to TumorsCancer Research, 2008
- Risk factors for major limb amputations in diabetic foot gangrene patientsDiabetes Research and Clinical Practice, 2006
- Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1Nature Medicine, 2004
- Growth factors in wound healingSurgical Clinics of North America, 2003
- Current understanding of stem cell mobilizationExperimental Hematology, 2002
- Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological NeovascularizationCirculation Research, 1999
- The future of recombinant growth factors in wound healingThe American Journal of Surgery, 1998